- Published: March 2011
Hepatitis B and C. Management and Treatment. Edition No. 2
- Published: August 2004
- Region: Global
- 168 Pages
- Informa Healthcare
Chronic hepatitis B and C affect 520 million people worldwide, and are a major cause of chronic liver disease and of mortality, despite the efficacy of the vaccine. Hepatitis B and C: Management and Treatment second edition provides a practical explanation of the natural history and management of the disease, and examines the benefits of the most recent drugs, and their effects, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of treatment of various difficult-to-treat patients and will be a welcome guide to the physician in both clinical decision-making and in explaining the benefits and side-effects to the patient.
Natural History of Hepatitis C: Epidemiology
Natural History of Hepatitis C: Hepatic Manifestations
Natural History of Hepatitis C: Extra-hepatic Manifestations and Quality of Life
Management Protocols in Chronic Hepatitis C
Management of Relapsers and Non Responders, Maintenance Therapy
Management of Patients with Cirrhosis
Management of Patients Co-infected by HCV and HIV
Management of HCV Infection Post Liver Transplantation
Management of Patients with Renal Disease
Safety of Interferon, Pegylated Interferon and Ribavirin
Who Need to be Treated?
Cost-effectiveness of Treatment. Management of Acute Hepatitis C
Practical Guidelines for the Management of Hepatitis C
New Drugs in Development
Natural History of Hepatitis B: Epidemiology
Natural History of Hepatitis B: Hepatic Manifestations
Natural History of Hepatitis B: Extra-hepatic Manifestations and Quality of Life
The Goal of Treatment in Chronic Hepatitis B
Efficacy of Interferon and Pegylated Interferon
Efficacy of Lamivudine
Efficacy of Adefovir
Comparison Between Lamivudine, Interferon and Adefovir, and Combinations
Safety of Lamivudine
Safety of Adefovir
New Drugs in Development
First Line Treatment of Chronic Hepatitis B: Adefovir, Lamivudine or Interferon?
Who Need to be Treated and How to Explain the Goals to the Patient?
Management of Relapsers and Non Responders
Management of Patients Co-infected by HBV and HIV
Management of Transplanted Patients Infected by HBV
Cost-effectiveness of Treatment.
Section 3: Biochemical Markers, an Alternative to Liver Biopsies
Advantage and Limits of Liver Biopsy
Advantage and Limits of Biochemical Markers
Thierry Poynard Groupe Hospitalier Piti¿-Salp¿tri¿re, Paris, France.